The positron emission tomography ligand DAA1106 binds with high affinity to activated microglia in human neurological disorders.
Chronic microglial activation is an important component of many neurological disorders, and imaging activated microglia in vivo will enable the detection and improved treatment of neuroinflammation. 1-(2-chlorphenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinoline-carbox-amide (PK11195), a peripheral benzodiazepine receptor ligand, has been used to image neuroinflammation, but the extent to which PK11195 binding distinguishes activated microglia and reactive astrocytes is unclear. Moreover, PK11195 may lack sufficient sensitivity for detecting mild neuroinflammation. We hypothesized that N-(2,5-dimethoxybenzyl)-N-(4-fluoro-2-phenoxyphenyl) acetamide (DAA1106), a new ligand that binds specifically to peripheral benzodiazepine receptor, binds to activated microglia in human neurological diseases with higher affinity than does PK11195. We therefore compared the pharmacological binding properties of [3H](R)-PK11195 and [3H]DAA1106 in postmortem tissues from patients with cerebral infarcts, amyotrophic lateral sclerosis, Alzheimer disease, frontotemporal dementia, and multiple sclerosis (n=10 each). In all diseases, [3H]DAA1106 showed a higher binding affinity as reflected by lower dissociation constant (KD) values than that of [3H](R)-PK11195. Moreover, specific binding of both ligands correlated with the presence of activated microglia identified by immunohistochemistry in situ. We conclude that 1) ligands that bind peripheral benzodiazepine receptor mainly label activated microglia in human neurological disorders and that 2) DAA1106 may possess binding characteristics superior to those of PK11195, which may be beneficial for in vivo positron emission tomography imaging.
Venneti
Sriram
S
Department of Pathology, University of Pittsburgh School of Medicine, and Presbyterian University Hospital, Neuropathology Division, Pittsburgh, Pennsylvania 15213, USA.
Wang
Guoji
G
Nguyen
Jason
J
Wiley
Clayton A
CA
D000081:Acetamides / Q000493:pharmacokinetics*; D000368:Aged; D000369:Aged, 80 and over; D001345:Autoradiography; D001921:Brain / Q000473:pathology; D005260:Female; D006801:Humans; D007249:Inflammation / Q000000981:diagnostic imaging / Q000473:pathology; D007546:Isoquinolines / Q000493:pharmacokinetics; D008297:Male; D017628:Microglia / Q000000981:diagnostic imaging* / Q000378:metabolism*; D008875:Middle Aged; D009422:Nervous System Diseases / Q000000981:diagnostic imaging* / Q000378:metabolism*; D010647:Phenyl Ethers / Q000493:pharmacokinetics*; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics*
D000081:Acetamides; C118942:DAA 1106; D007546:Isoquinolines; D010647:Phenyl Ethers; D019275:Radiopharmaceuticals; C037850:PK 11195
Lancet. 1992 Apr 25;339(8800):1054-5
1349076
Neurobiol Dis. 2008 Feb;29(2):232-41
17920902
Exp Neurol. 2000 Jan;161(1):102-14
10683277
J Neurochem. 2000 Apr;74(4):1694-704
10737628
Neuroreport. 2000 Sep 11;11(13):2957-60
11006973
Brain. 2000 Nov;123 ( Pt 11):2321-37
11050032
Neurology. 2000 Oct 10;55(7):1052-4
11061271
Lancet. 2001 Aug 11;358(9280):461-7
11513911
Brain. 2001 Oct;124(Pt 10):2014-27
11571219
Glia. 2002 Nov;40(2):206-17
12379908
Eur J Neurol. 2003 May;10(3):257-64
12752399
J Clin Invest. 2004 Apr;113(7):981-9
15057304
Neurobiol Dis. 2004 Apr;15(3):601-9
15056468
Brain. 2004 Jun;127(Pt 6):1379-92
15069023
Mov Disord. 2004 Oct;19(10):1221-6
15390000
J Cereb Blood Flow Metab. 1991 Mar;11(2):314-22
1997503
Eur J Pharmacol. 1991 Aug 6;200(2-3):347-51
1782994
Neurosci Lett. 1994 Aug 15;177(1-2):35-8
7824177
J Neurosci. 1995 Jul;15(7 Pt 2):5263-74
7623150
J Nucl Med. 1995 Dec;36(12):2207-10
8523106
J Neurocytol. 1997 Feb;26(2):77-82
9181482
J Neurosci Res. 1997 Oct 15;50(2):345-53
9373043
Eur J Pharmacol. 1997 Dec 4;340(1):89-99
9527511
Neuroscience. 1998 Feb;82(3):805-17
9483537
Eur J Pharmacol. 1999 Apr 29;371(2-3):197-204
10357257
Neurosci Lett. 1999 Aug 13;271(1):5-8
10471200
Ann Neurol. 2004 Dec;56(6):894-7
15562429
Neuroimage. 2005 Jan 15;24(2):591-5
15627603
Ann Neurol. 2005 Feb;57(2):168-75
15668962
Mult Scler. 2005 Apr;11(2):127-34
15794383
J Neurovirol. 2005 Aug;11(4):346-55
16162478
Neurobiol Dis. 2005 Nov;20(2):550-61
15916899
Neurobiol Dis. 2006 Feb;21(2):404-12
16182554
Gut. 2006 Apr;55(4):547-53
16210399
J Neuropathol Exp Neurol. 2006 Mar;65(3):199-203
16651881
Neurology. 2006 Jun 13;66(11):1638-43
16769933
Stroke. 2006 Jul;37(7):1749-53
16763188
Eur J Neurosci. 2006 Aug;24(4):991-1000
16930426
J Neurovirol. 2006 Aug;12(4):262-71
16966217
Nat Rev Neurosci. 2007 Jan;8(1):57-69
17180163
Prog Neurobiol. 2006 Dec;80(6):308-22
17156911
Brain. 2007 Jul;130(Pt 7):1759-66
17400599
Neurology. 1999 Dec 10;53(9):2199-203
10599809